Albany, NY -- (SBWIRE) -- 07/23/2019 -- Wilson's Disease Market Insights, Epidemiology and Market Forecast-2028
1. Wilson's disease occurs in approximately 1 in 30,000 to 40,000 people worldwide.
2. There may be 9,000 people affected by Wilson's disease in the United States.
3. About 1 in 7,000 people have gene mutations that cause Wilson disease in the United Kingdom.
DelveInsight launched a new report on Wilson's disease Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Wilson's disease market report covers a descriptive overview and comprehensive insight of Wilson's disease epidemiology and Wilson's disease market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Wilson's disease market report provides insights into current and emerging therapies.
3. Wilson's disease market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Wilson's disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving Wilson's disease market.
Request for sample pages
"People who have Wilson disease typically develop symptoms when they are between ages 5 and 40.3"
Wilson disease is a treatable condition. With proper therapy, disease progress can be halted and often Wilson disease symptoms can be improved. Wilson disease treatment is aimed at removing excess accumulated copper and preventing its re-accumulation. Chelation therapy drugs approved for Wilson disease treatment include penicillamine and trientine. Both of these drugs act by chelation or binding of copper, causing its increased urinary excretion.
Though there are many therapies available for Wilson's Disease treatment, yet more research is necessary to overcome the side-effects caused by Wilson's Disease approved therapies. Due to side effects, and non-specific mechanism of action, constrain patients to take medication several times a day life-long. Being a lifelong disease, frequently diagnosed in the pediatric age, and requirement daily intake of one or more pharmacological agents, oftentimes two or three times daily, adherence can sometimes be an issue and can lead to life-threatening deterioration of clinical conditions. It is important to look out for overtreatment, which presents with neutropenia and anaemia, due to failed iron mobilization, with transaminase elevation due to increased hepatic iron, accompanied by increased ferritin. The rising number of Wilson Disease patients, increasing awareness, and increasing research and development activities are some of the factors which are expected to contribute towards Wilson Disease market growth during the forecast period (2019-2028).
The dynamics of Wilson's Disease market is anticipated to change in the coming years owing to the already approved drugs, improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world and expected the launch of emerging therapies during the forecast period of 2019-2028. There are many promising candidates in the late stage of clinical development which are expected to create an impact on Wilson's Disease market during the forecast period.
The launch of the late phase upcoming therapies such as mentioned below shall increase Wilson's Disease market size during the forecast period:-
1. TETA 4HCL
2. WTX101
And many others
The key players in Wilson's Disease market are
1. GMP-Orphan SAS
2. Alexion
And many others
Table of contents
1. Key Insights
2. Wilson's Disease Market Overview at a Glance
3. Wilson's Disease Disease Background and Overview
4. Wilson's Disease Epidemiology and Patient Population
5. Wilson's Disease 7MM Total Prevalent Patient Population
5.1. United States
5.2. Germany
5.3. France
5.4. Italy
5.5. Spain
5.6. United Kingdom
5.7. Japan
6. Wilson's Disease Current Treatment and Medical Practices
7. Wilson's Disease Unmet Needs
8. Wilson's Disease Marketed drugs
8.1. Cuprimine: Valeant Pharmaceuticals
8.2. Syprine: Valeant Pharmaceuticals
8.3. Galzin: Teva Pharmaceuticals
9. Wilson's Disease Emerging Drugs
9.1. TETA 4HCL: GMP-Orphan SAS
9.2. WTX101: Alexion
10. Wilson's Disease 7 Major Market Analysis
11. Market Outlook by Country
11.1. The United States: Market Outlook
11.2. EU-5 Countries: Market Outlook
11.3. Germany
11.4. France
11.5. United Kingdom
11.6. Spain
11.7. Italy
11.8. Japan
12. Market Drivers
13. Market Barriers
14. Appendix
15. Report Methodology
16. DelveInsight Capabilities
17. Disclaimer
18. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight